Organovo Announces Release Date for Fiscal Third-Quarter 2018 Financial Results
January 18 2018 - 8:05AM
Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a
conference call on Thursday, February 8, 2018 at 5:00 p.m. Eastern
Time (ET) to discuss the Company's fiscal third-quarter 2018
financial results. In advance of the call on February 8,
2018, Organovo will issue its fiscal third-quarter 2018 earnings
press release, which will be available at
http://www.organovo.com. To participate in the
teleconference, callers can dial the following numbers:
1-888-317-6003 (toll-free, U.S. callers only)
1-412-317-6061 (from outside the U.S.)
Conference Call ID: 2242366
To help ensure the conference call begins in a timely manner,
please dial in five minutes prior to the scheduled start
time. The conference call will also be simultaneously webcast
at http://www.organovo.com.
For those unable to participate in the live call, a replay of
the call will be available toll-free until February 15, 2018 at
1-877-344-7529 (U.S. callers only) or at 1-412-317-0088 (callers
outside the U.S.). The passcode for the replay is:
10115734. An archived replay of the webcast will also be
available at http://www.organovo.com.
About Organovo Holdings, Inc.Organovo designs
and creates functional, three-dimensional human tissues for use in
drug discovery, clinical development, and therapeutic
applications. The Company develops 3D human tissue systems
through internal research programs and in collaboration with
pharmaceutical, academic and other partners. Organovo's 3D
human tissues have the potential to transform the drug discovery
process, enabling treatments to be developed more effectively and
with greater relevance to performance in human trials and
commercialization. The Company’s ExVive™ Human Liver and
Kidney Tissues are used in high-value drug profiling, including
compound screening in disease models, toxicology, target and marker
discovery/validation, and other drug testing. The Company is
also advancing a preclinical program to develop its NovoTissues®
liver therapeutic tissues for critical unmet medical needs,
including certain life-threatening pediatric diseases. In
addition to numerous scientific publications, the Company’s
technology has been featured in The Wall Street Journal, Time
Magazine, The Economist, Forbes, and numerous other media
outlets. Organovo is changing the shape of life science
research and transforming medical care. Learn more at
www.organovo.com.
Forward-Looking StatementsAny statements
contained in this press release that do not describe historical
facts constitute forward-looking statements as that term is defined
in the Private Securities Litigation Reform Act of 1995. Any
forward-looking statements contained herein are based on current
expectations, but are subject to a number of risks and
uncertainties. The factors that could cause the Company's
actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the Company's ability to develop, market
and sell products and services based on its technology; the
expected benefits and efficacy of the Company's products, services
and technology; the Company’s ability to successfully complete
studies and provide the technical information required to support
market acceptance of its products, services and technology, on a
timely basis or at all; the Company's business, research, product
development, regulatory approval, marketing and distribution plans
and strategies, including its use of third party distributors; the
Company's ability to secure additional contracted collaborative
relationships; the final results of the Company's preclinical
studies may be different from the Company's studies or interim
preclinical data results and may not support further clinical
development of its therapeutic tissues; the Company may not
successfully complete the required preclinical and clinical trials
required to obtain regulatory approval for its therapeutic tissues
on a timely basis or at all; the Company’s ability to control the
costs and to achieve the expected operational benefits and long-
term cost savings of its previously announced restructuring plan;
and the Company’s ability to meet its fiscal year 2018 outlook.
These and other factors are identified and described in more detail
in the Company's filings with the SEC, including its Annual Report
on Form 10-K filed with the SEC on June 7, 2017. You should not
place undue reliance on these forward-looking statements, which
speak only as of the date that they were made. These cautionary
statements should be considered with any written or oral
forward-looking statements that the Company may issue in the
future. Except as required by applicable law, including the
securities laws of the United States, the Company does not intend
to update any of the forward-looking statements to conform these
statements to reflect actual results, later events or circumstances
or to reflect the occurrence of unanticipated events.
Investor Contact:
Steve Kunszabo
Organovo Holdings, Inc.
+1 (858) 224-1092
skunszabo@organovo.com
Press Contact:
Jessica Yingling
Little Dog Communications
+1 (858) 480-2411
jessica@litldog.com
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Organovo (NASDAQ:ONVO)
Historical Stock Chart
From Sep 2023 to Sep 2024